Liver transplantation for hilar cholangiocarcinoma

World J Gastroenterol. 2013 Dec 28;19(48):9209-15. doi: 10.3748/wjg.v19.i48.9209.

Abstract

The most appropriate treatment for Klatskin tumor (KT) with a curative intention is multimodal therapy based on achieving resection with tumour-free margins (R0 resections) combined with other types of neoadjuvant or adjuvant treatment (the most important factor affecting KT survival is the possibility of R0 resections, achieving 5-year survival rate of 40%-50%). Thirty to forty percent of patients with KT are inoperable and present a 5-year survival rate of 0%. In irresectable non-disseminated KT patients, using liver transplantation without neoadjuvant treatment, the 5-year survival rate increase to 38%, reaching 50% survival in early stage. In selected cases, with liver transplantation and neoadjuvant treatment (chemotherapy and radiotherapy), the actuarial survival rate is 65% at 5 years and 59% at 10 years. In conclusion, correct staging, neoadjuvant treatment, living donor and priority on the liver transplant waiting list may lead to improved results.

Keywords: Cholangiocarcinoma; Klatskin tumour; Liver surgery; Liver transplantation; Primary sclerosing cholangitis.

Publication types

  • Review

MeSH terms

  • Bile Duct Neoplasms / mortality
  • Bile Duct Neoplasms / pathology
  • Bile Duct Neoplasms / surgery*
  • Bile Ducts, Intrahepatic / pathology
  • Bile Ducts, Intrahepatic / surgery*
  • Chemotherapy, Adjuvant
  • Cholangiocarcinoma / mortality
  • Cholangiocarcinoma / pathology
  • Cholangiocarcinoma / surgery*
  • Hepatic Duct, Common / pathology
  • Hepatic Duct, Common / surgery*
  • Humans
  • Klatskin Tumor / mortality
  • Klatskin Tumor / pathology
  • Klatskin Tumor / surgery*
  • Liver Transplantation* / adverse effects
  • Liver Transplantation* / mortality
  • Living Donors
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Waiting Lists